An update of current treatments for adult acute myeloid leukemia - Test2 - elhamkhani - TriplyDB

An update of current treatments for adult acute myeloid leukemia

An update of current treatments for adult acute myeloid leukemia

http://www.wikidata.org/entity/Q26776396

about

Epimutational profile of hematologic malignancies as attractive target for new epigenetic therapies The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia.Tyrosine kinase inhibitors targeting FLT3 in the treatment of acute myeloid leukemia.SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.GATA2 Inhibition Sensitizes Acute Myeloid Leukemia Cells to Chemotherapy Acute myeloid leukemia in the era of precision medicine: recent advances in diagnostic classification and risk stratification.Cathepsin G is broadly expressed in acute myeloid leukemia and is an effective immunotherapeutic target.Acute myeloid leukemia - strategies and challenges for targeting oncogenic Hedgehog/GLI signaling Acute Myeloid Leukemia: Advancements in Diagnosis and Treatment.Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel.Targeting prohibitins induces apoptosis in acute myeloid leukemia cells.Proteogenomics approaches for studying cancer biology and their potential in the identification of acute myeloid leukemia biomarkers.Single-Cell Mass Cytometry of Acute Myeloid Leukemia and Leukemia Stem/Progenitor Cells.Investigational BET bromodomain protein inhibitors in early stage clinical trials for acute myelogenous leukemia (AML).Identifying high-risk adult AML patients: epigenetic and genetic risk factors and their implications for therapy.Proteasome inhibition enhances the efficacy of volasertib-induced mitotic arrest in AML in vitro and prolongs survival in vivo Interferon-γ Promotes Antibody-mediated Fratricide of Acute Myeloid Leukemia Cells.Plasma-derived exosomes in acute myeloid leukemia for detection of minimal residual disease: are we ready?Hypomethylating Agents as a Therapy for AML.Allogeneic transplantation for advanced acute myeloid leukemia: The value of complete remission.What Is the Best Daunorubicin Dose and Schedule for Acute Myeloid Leukemia Induction?Midostaurin: First Global Approval.Drug discovery and therapeutic delivery for the treatment of B and T cell tumors.Therapy-related Acute Myeloid Leukemia after the Long-term Administration of Low-dose Etoposide for Chronic-type Adult T-cell Leukemia-lymphoma: A Case Report and Literature Review.Condensed versus standard schedule of high-dose cytarabine consolidation therapy with pegfilgrastim growth factor support in acute myeloid leukemia.Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.Active hexose-correlated compound enhances extrinsic-pathway-mediated apoptosis of Acute Myeloid Leukemic cells.The collagen receptor uPARAP/Endo180 as a novel target for antibody-drug conjugate mediated treatment of mesenchymal and leukemic cancers.Immunotherapeutic Concepts to Target Acute Myeloid Leukemia: Focusing on the Role of Monoclonal Antibodies, Hypomethylating Agents and the Leukemic Microenvironment.Impact of marital status during diagnosis on cancer-caused specific survival in acute myeloid leukemia patients: a case-control and population-based study.Antibody darts on target for acute myelogenous leukemia.Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia.Expression of the miR-148/152 Family in Acute Myeloid Leukemia and its Clinical Significance.Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis.High-throughput profiling of signaling networks identifies mechanism-based combination therapy to eliminate microenvironmental resistance in acute myeloid leukemia.The Natural Antiangiogenic Compound AD0157 Induces Caspase-Dependent Apoptosis in Human Myeloid Leukemia Cells.A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.Randomized phase II trial of cytosine arabinoside with and without the CHK1 inhibitor MK-8776 in relapsed and refractory acute myeloid leukemia.Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells' vulnerability to DNA-damaging agents.

P2860

Q26744080-4B34261B-93DC-4E20-873B-67A316030BF9 Q30252512-25331FDB-4466-47DA-97E5-CD90622F8265 Q33767026-DEED6FD4-D8C4-4C54-8304-AA367F4AC211 Q34547626-2BEDCE69-C921-429E-A1BC-453ED421BB35 Q36257547-99A1F5F2-F258-4727-A96F-780DC041FA3C Q36849666-B9BF9925-C2BC-43D1-9055-F68F32412049 Q37561181-5E10BF9B-EBC1-4867-938F-2B07BEC15C4D Q37607838-F7B43F00-4412-44E9-955F-D11C047DD5CE Q37615574-F80CEEB9-6C28-4684-8153-7E92437253D2 Q37624593-EE2EA248-D76A-4980-BDF6-4B27649EB1A6 Q37662175-7157D4F2-A7D5-4245-88D8-709F6792AF61 Q38660073-5A977D11-F16E-4FBF-A57E-414C3E35B8BE Q38666230-2F2FE7BD-88A0-450E-92AF-BCC46ECC80C3 Q38679327-5AE4E077-4567-46EE-A2F6-EA5D4CCE92EA Q38694866-4D762E59-47E3-441D-BED2-982456C7C98E Q38707201-D6562586-8550-4457-A429-92AD89696548 Q38736778-2C1B3689-37E5-439C-8F60-8A6F2263CFB2 Q38886247-939AEAE6-AA90-499D-8DDC-FF747289E3E8 Q38911864-D17DC04F-B527-4F96-847B-14D7383A6121 Q39002077-E0EB947C-3E9D-46AC-B6EE-A5A5D2B89D64 Q39116969-62CA3F56-C8E8-4194-8E15-10B1268E98C5 Q39371391-0201EF5A-59AF-4B12-AF45-99F2C641CB0E Q39381251-6D832442-E9B0-4353-92CE-7516A63F8C4B Q39440364-38A10F6F-F14F-4299-870C-AC47AE34659E Q40197450-B9D9EB77-55A6-4619-A19C-C82914096FE3 Q40314122-093C3EC1-A6DD-45FB-8170-A8958D7B4937 Q41072362-631AE22B-55E8-474D-92DD-7293BA9656FF Q41280225-6DEB917F-33B3-4C2C-A240-0C18D93B1C58 Q41573313-05EDE4EB-67C8-4A39-A721-150ED659CEB1 Q41839924-B799B348-D1FC-4B80-A172-365BFCE40F4B Q42318343-473BE5AD-5F8B-4ED7-AD89-A977E5D83675 Q42363757-04B1B158-E662-4F63-8B46-33E046256FC6 Q42376720-FF9F3C06-667D-42C9-94DF-836F05C7E2C5 Q42376734-414B3527-F342-43A0-A72D-1F9E05B86C61 Q45120868-E0C1BD8F-1796-4F6D-8CD8-1A37AD12E56D Q45383909-116B710D-AE2A-4556-9C7E-413D555F221B Q46744333-7F25C21A-0339-4626-BFE9-F72E4E1F4917 Q47156715-3F1773F7-6CE2-46FC-A61B-F6733982D23E Q47730914-2507E256-7AD8-4D6A-AB6F-3259C96A311C Q47808353-39F858B9-C92B-43C1-A53E-6866AE1FA4E8

P2860

An update of current treatments for adult acute myeloid leukemia

http://www.wikidata.org/entity/Q26776396

description

2016 nî lūn-bûn

@nan

2016 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2016 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

name

An update of current treatments for adult acute myeloid leukemia

@ast

An update of current treatments for adult acute myeloid leukemia

@en

An update of current treatments for adult acute myeloid leukemia

@nl

type

label

An update of current treatments for adult acute myeloid leukemia

@ast

An update of current treatments for adult acute myeloid leukemia

@en

An update of current treatments for adult acute myeloid leukemia

@nl

prefLabel

An update of current treatments for adult acute myeloid leukemia

@ast

An update of current treatments for adult acute myeloid leukemia

@en

An update of current treatments for adult acute myeloid leukemia

@nl

P1433

Q26776396-847E6FB0-0B69-4D45-8675-6412228EAA7F

P1476

Q26776396-BA69C98D-04F3-4A44-A27D-936867107B43

P2093

Q26776396-327981F9-6547-4AD8-BC2E-8A6DBD0AC208

P2860

Q26776396-05D1348B-22A3-49B2-837B-CD59A45F35F4

Q26776396-08C94DC0-3F0E-4D1A-B610-26CAC87C81CE

Q26776396-0B534169-7177-42F2-BB11-EE531905CB89

Q26776396-0BBAA1A6-EDC8-4D23-9966-086E6A9D0958

Q26776396-1CBCD02D-FA1D-4DE8-B5E3-979280CCDE7F

Q26776396-1D490F6A-F6DF-44F2-92E1-D245DF356306

Q26776396-270B43BE-9E9F-47CC-A8B1-2B0C766E8F5C

Q26776396-27959776-C187-40DD-A9F3-20403D8F301C

Q26776396-2D1F787B-DDDD-40AB-84A0-6A2D8AB44EB8

Q26776396-34665D92-2870-402C-BE9C-682B2BEC7C9E

P304

Q26776396-01C56F11-49B0-426A-8E89-D374D8BE025F

P31

Q26776396-CAF8A7B2-433A-4100-89B9-7FA0E05B0FFA

P3181

Q26776396-6B7F88DE-106D-4D6B-9121-FB76F346602A

P356

Q26776396-29A4F447-944B-4FC0-9C0B-9B38FD4F6660

P407

Q26776396-9601FFEA-CDC2-4E55-96D0-502D424456FA

P433

Q26776396-F5AFF5F4-3FA3-4178-94D2-2957574DDD89

P478

Q26776396-840F684C-49E8-40A7-972F-3A052E726EC8

P50

Q26776396-286D7AB8-3B20-4DF5-A3D0-DB337388DA2A

P577

Q26776396-D69527A2-852E-49AC-837F-2DEF3FB89230

P5875

Q26776396-59031BA5-6749-4F79-8036-7F22424B57AA

P698

Q26776396-96C2F21A-F27D-411C-BCB1-4FF9B68C8F87

P921

Q26776396-4A2195A5-9233-43FC-8EFB-D202B13C8327

Q26776396-64146FEC-3B35-4F57-8E1E-E9946AC6C915

P932

Q26776396-7B4F2BCF-ABA5-412E-A200-47B0E6564582

P3181

P356

BLOOD-2015-08-604520

P1433

P1476

An update of current treatments for adult acute myeloid leukemia

@en

P2093

Claude Gardin

http://www.w3.org/2001/XMLSchema#string

P2860

Post-transplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation

Post-remission therapy for acute myeloid leukemia

Defining minimal residual disease in acute myeloid leukemia: which platforms are ready for "prime time"?

Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia.

Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B.

Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study.

Impact of FLT3(ITD) mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia.

The impact on outcome of the addition of all-trans retinoic acid to intensive chemotherapy in younger patients with nonacute promyelocytic acute myeloid leukemia: ...

Secondary mutations as mediators of resistance to targeted therapy in leukemia

Intensive postremission chemotherapy in adults with acute myeloid leukemia. Cancer and Leukemia Group B

P304

53-61

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4774988

http://www.w3.org/2001/XMLSchema#string

P356

10.1182/BLOOD-2015-08-604520

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

127

http://www.w3.org/2001/XMLSchema#string

P50

P577

2016-01-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

286476713

http://www.w3.org/2001/XMLSchema#string

P698

26660429

http://www.w3.org/2001/XMLSchema#string

P921

P932

4705610

http://www.w3.org/2001/XMLSchema#string